摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

16-bromo-1-hexadecanethiol | 1362855-77-3

中文名称
——
中文别名
——
英文名称
16-bromo-1-hexadecanethiol
英文别名
16-Bromo-1-hexadecanethiol;16-bromohexadecane-1-thiol
16-bromo-1-hexadecanethiol化学式
CAS
1362855-77-3
化学式
C16H33BrS
mdl
——
分子量
337.408
InChiKey
DYYIACMPWUIXJX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    8.1
  • 重原子数:
    18
  • 可旋转键数:
    15
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    1
  • 氢给体数:
    1
  • 氢受体数:
    1

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    octa acid 、 16-bromo-1-hexadecanethiol 在 sodium hydroxide 作用下, 以 重水 为溶剂, 生成
    参考文献:
    名称:
    Electrostatic Control of Macrocyclization Reactions within Nanospaces
    摘要:
    The intrinsic structural complexity of proteins makes it hard to identify the contributions of each noncovalent interaction behind the remarkable rate accelerations of enzymes. Coulombic forces are evidently primary, but despite developments in artificial nanoreactor design, a picture of the extent to which these can contribute has not been forthcoming. Here we report on two supramolecular capsules that possess structurally identical inner-spaces that differ in the electrostatic potential (EP) field that envelops them: one positive and one negative. This architecture means that only changes in the EP field influence the chemical properties of encapsulated species. We quantify these influences via acidity and rates of cyclization measurements for encapsulated guests, and we confirm the primary role of Coulombic forces with a simple mathematical model approximating the capsules as Born spheres within a continuum dielectric. These results reveal the reaction rate accelerations possible under Coulombic control and highlight important design criteria for nanoreactors.
    DOI:
    10.1021/jacs.9b02287
  • 作为产物:
    描述:
    1,16-二溴十六烷sodium methylate乙酰氯 作用下, 以 甲醇 为溶剂, 反应 4.0h, 生成 16-bromo-1-hexadecanethiol
    参考文献:
    名称:
    Cationic surface modification of gold nanoparticles for enhanced cellular uptake and X-ray radiation therapy
    摘要:
    具有阳离子表面修饰的金纳米颗粒可以通过增强细胞摄取来增强X射线放疗的效果。
    DOI:
    10.1039/c5tb00766f
点击查看最新优质反应信息

文献信息

  • Cationic surface modification of gold nanoparticles for enhanced cellular uptake and X-ray radiation therapy
    作者:Chaoming Wang、An Sun、Yong Qiao、Peipei Zhang、Liyuan Ma、Ming Su
    DOI:10.1039/c5tb00766f
    日期:——

    Gold nanoparticles with cationic surface modification can enhance X-ray radiation therapy by enhancing cellular uptake.

    具有阳离子表面修饰的金纳米颗粒可以通过增强细胞摄取来增强X射线放疗的效果。
  • Quantitative Replacement of Cetyl Trimethylammonium Bromide by Cationic Thiol Ligands on the Surface of Gold Nanorods and Their Extremely Large Uptake by Cancer Cells
    作者:Leonid Vigderman、Pramit Manna、Eugene R. Zubarev
    DOI:10.1002/anie.201107304
    日期:2012.1.16
    Stable and biocompatible: The chemical composition of synthesized cationic thiolate‐monolayer‐protected gold nanorods was precisely determined. In vitro cell culture experiments showed no cytotoxicity of these nanorods, and the number of nanorods that were taken up by each cancer cell exceeded two million particles (see picture).
    稳定且具有生物相容性:精确确定了合成的阳离子硫醇盐单层保护的金纳米棒的化学组成。体外细胞培养实验显示这些纳米棒没有细胞毒性,每个癌细胞吸收的纳米棒数量超过200万个颗粒(见图)。
  • DRUG DELIVERY FROM IMPLANTS USING SELF-ASSEMBLED MONOLAYERS-THERAPEUTIC SAMS
    申请人:Agrawal C. Mauli
    公开号:US20090123516A1
    公开(公告)日:2009-05-14
    Disclosed are medical devices comprising one or more surfaces, one or more SAM molecules attached to the one or more surfaces of the medical device, and one or more therapeutic agents attached to the one or more self-assembled monolayer molecules. Also disclosed are medical devices comprising one or more surfaces, one or more self-assembled monolayer molecules attached to the one or more surfaces of the medical device, one or more linkers comprising a first functional group and a second functional group, the first functional group attached to the self-assembled monolayer molecule and a therapeutic agent attached to the second functional group. The therapeutic agent may be attached to the SAM molecule via a linker. The present invention also concerns methods of administering a therapeutic agent to a subject, comprising contacting the subject with one of the medical devices set forth herein.
  • [EN] DRUG DELIVERY FROM IMPLANTS USING SELF-ASSEMBLED MONOLAYERS - THERAPEUTIC SAMS<br/>[FR] LIBERATION DE MEDICAMENTS PAR DES IMPLANTS COMPRENANT DES MONOCOUCHES AUTO-ASSEMBLEES (SAM) SAM THERAPEUTIQUES
    申请人:UNIV TEXAS
    公开号:WO2007019478A2
    公开(公告)日:2007-02-15
    [EN] Disclosed are medical devices comprising one or more surfaces, one or more SAM molecules attached to the one or more surfaces of the medical device, and one or more therapeutic agents attached to the one or more self-assembled monolayer molecules. Also disclosed are medical devices comprising one or more surfaces, one or more self-assembled monolayer molecules attached to the one or more surfaces of the medical device, one or more linkers comprising a first functional group and a second functional group, the first functional group attached to the self-assembled monolayer molecule and a therapeutic agent attached to the second functional group. The therapeutic agent may be attached to the SAM molecule via a linker. The present invention also concerns methods of administering a therapeutic agent to a subject, comprising contacting the subject with one of the medical devices set forth herein.
    [FR] L'invention concerne des dispositifs médicaux comprenant une ou plusieurs surfaces, une ou plusieurs molécules SAM attachées à une ou plusieurs surfaces du dispositif médical, et un ou plusieurs agents thérapeutiques fixés sur les molécules de la ou des monocouches auto-assemblées. L'invention concerne en outre des dispositifs médicaux comprenant une ou plusieurs surfaces, une ou plusieurs molécules de monocouche auto-assemblée fixées à la surface ou aux surfaces du dispositif médical, un ou plusieurs lieurs comprenant un premier groupe fonctionnel et un second groupe fonctionnel, le premier groupe fonctionnel étant attaché à la molécule de la monocouche auto-assemblée, et un agent thérapeutique attaché au second groupe fonctionnel. L'agent thérapeutique peut être fixé sur la molécule SAMS par l'intermédiaire d'un lieur. L'invention porte également sur des procédés d'administration d'un agent thérapeutique à un sujet consistant appliquer un dispositif médical du type décrit à un sujet.
  • Electrostatic Control of Macrocyclization Reactions within Nanospaces
    作者:Kaiya Wang、Xiaoyang Cai、Wei Yao、Du Tang、Rhea Kataria、Henry S. Ashbaugh、Larry D Byers、Bruce C. Gibb
    DOI:10.1021/jacs.9b02287
    日期:2019.4.24
    The intrinsic structural complexity of proteins makes it hard to identify the contributions of each noncovalent interaction behind the remarkable rate accelerations of enzymes. Coulombic forces are evidently primary, but despite developments in artificial nanoreactor design, a picture of the extent to which these can contribute has not been forthcoming. Here we report on two supramolecular capsules that possess structurally identical inner-spaces that differ in the electrostatic potential (EP) field that envelops them: one positive and one negative. This architecture means that only changes in the EP field influence the chemical properties of encapsulated species. We quantify these influences via acidity and rates of cyclization measurements for encapsulated guests, and we confirm the primary role of Coulombic forces with a simple mathematical model approximating the capsules as Born spheres within a continuum dielectric. These results reveal the reaction rate accelerations possible under Coulombic control and highlight important design criteria for nanoreactors.
查看更多